Biotalys shares soar nearly 18% after Dutch green light for Evoca NG
The stock posts a very strong gain during the session, following a regulatory authorisation in the Netherlands. The move brings the share price back to technical levels that have been monitored for several weeks.
A Ctgb green light to test Evoca NG on commercial surfaces
The Dutch plant protection products regulator (Ctgb) has authorised Biotalys to have its next-generation biofungicide, Evoca NG, on 350 hectares, tested by producers. According to the press release published on 3 November 2026, the harvests from these plots may enter the food chain.
The share of Biotalys gains 17.89% to €1.90, compared with €1.61 the previous day, while the CAC 40 is virtually flat. It also shows a 17.5% increase over one week, but remains down 23% over three months.
When publishing its H1 2026 results (on 20 August 2026), the company indicated that its cash would only cover the period until the end of the first quarter of 2027, and targeted a launch of Evoca NG in 2029 in the United States and in 2030 in Europe.
A share price back above its MM20, below its MM50 at €1.97
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The stock sits 11% above its MM20 (€1.71), which it has therefore comfortably regained. It remains below its MM50, at €1.97, about 3.7% above the current price.
Resistance at €2.02 lies just over 6% above the current level. The RSI at 59 remains neutral despite the magnitude of the jump, a sign that the day's rise follows a long decline. The €2.02 level is the closest technical benchmark in the data.
Biotalys intends to maintain a cost-conscious approach to fully exploit the potential of its unique technology platform
Risks mentioned
Limited financial runway of only until end of Q1 2027 requiring additional financing
Regulatory approval delays in U.S. and E.U. for EVOCA and EVOCA NG could impact commercialisation timeline
Dependence on successful manufacturing scale-up and partnerships to achieve commercial viability of lead products
Opportunities identified
Regulatory approval pathway for EVOCA NG in U.S. (2029 launch) and Europe (2030 launch) targeting USD 1.1 billion market
BioFun-6 lead candidate demonstrating strong efficacy in field trials across multiple crops and geographies
Strategic partnership with 21st.BIO for manufacturing efficiencies and commercially competitive cost structure
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
